Ximelagatran: Pharmacology, pharmacokinetics, and pharmacodynamics

Pharmacotherapy

Volumn 24, Issue 10 I, 2004, Pages

  Dobesh, Paul P ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Pharmacology; Thromboembolism; Venous thromboembolic disease; Warfarin; Ximelagatran

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTIVITAMIN K; ATORVASTATIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450; DALTEPARIN; DIAZEPAM; DICLOFENAC; DIGOXIN; ERYTHROMYCIN; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NIFEDIPINE; PROTHROMBIN; THROMBIN; WARFARIN; XIMELAGATRAN;

AREA UNDER THE CURVE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG USE; FOOD DRUG INTERACTION; HUMAN; LIVER FUNCTION TEST; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; AZETIDINES; BENZYLAMINES; CLINICAL TRIALS, PHASE III; CROSS-OVER STUDIES; HUMANS; META-ANALYSIS;

EID: 4644327496     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.15.169S.43160     Document Type: Review

References (62)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8.
2. Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999;30:2523-8.
3. Tavazzi L. Clinical epidemiology of acute myocardial infarction. Am Heart J 1999;138:S48-54.
4. American Heart Association. 2003 heart and stroke statistical update. Dallas, TX: American Heart Association, 2002.
5. Giesen PL, Rausch U, Bohrmann B, Kling D, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-15.
6. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Verastraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis, 2nd ed. Philadelphia: Lippincott-Raven, 1998:3-22.
7. Colman RW, Clowes AW, George JH, Hirsch JL, Marder VJ. Overview of homeostasis. In: Hemostasis and thrombosis: basic principles and clinical practice, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:3-16.
8. Dahlback B. Blood coagulation. Lancet 2000;355:1627-32.
9. Bajzar L, Manual R, Nesheim ME. Purification and characteristics of TAF1, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-84.
10. Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost 1995;74:352-9.
11. Graham DJ, Alexander JJ. The effect of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg 1990;11:307-13.
12. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002;39:187-96.
13. Carvalho AC, Freeman NJ. How coagulation defects alter outcome in sepsis: survival may depend on reversing procoagulant conditions. J Crit Illness 1994;9:51-75.
14. Levi M, Cate HT, van der Poll T, van Deventer H. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-9.
15. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21.
16. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulation therapy. Chest 2001;119:22S-38.
17. Levine MN, Raskob G, Landerfeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108S-21.
18. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complications. Lancet 1999;353:717-19.
19. Gustafsson D, Nystrom J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-81.
20. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522-36.
21. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-6.
22. Verstraete M, Zoldhelyi P, Willerson JT. Specific thrombin inhibitors. In: Verastraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis, 2nd ed. Philadelphia: Lippincott-Raven, 1998:141-72.
23. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-18.
24. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004;38:99-109.
25. Bostrom SL, Hansson GFH, Kjaer M, Sarich TC. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 2003;14:457-62.
26. Mattsson C, Bjorkman JA, Ulvinge JC, et al. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in the canine model of coronary artery thrombolysis. Fibrinol Proteolys 1997;11:121-8.
27. Mattsson C, Bjorkman JA, Abrahamsson T, et al. Local proCPU (TAF1) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002;87:557-62.
28. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. J Thromb Haemost 1999;81:358-63.
29. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1:41-7.
30. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metabol Dispos 2003;31:294-305.
31. Gustasson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003;254:322-34.
32. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59:35-43.
33. Johansson LC, Prison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-92.
34. Wolzt M, Wollbratt M, Svensson M, Wahlander K, Margaretha G, Eriksson UG. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 2003;59:537-43.
35. Sarich TC, Teng R, Peters GR, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003;42:485-92.
36. Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003;42:475-84.
37. Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran. Clin Pharmacokinet 2003;42:687-701.
38. Eriksson UG, Johansson S, Attman P-O, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003;42:743-53.
39. Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:755-64.
40. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-77.
41. Anderson TB. Activation of ximelagatran, melagatran's prodrug [abstr]. Drug Metab Rev 2001;33(suppl 1):8.
42. Dorani H, Schutzer K, Wollbratt M, et al. No clinically significant interactions between the oral direct thrombin inhibitor ximelagatran and amiodarone, atorvastatin, or digoxin [abstr]. Clin Pharmacol Ther 2004;75:P78.
43. Dorani H, Schutzer K, Sarich TC, et al. Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran [abstr]. Clin Pharmacol Ther 2004;75:P78.
44. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
45. The OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with myocardial infarction without ST elevation: a randomized trial. Lancet 1999;353:429-38.
46. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model for arterial thrombosis. Thromb Haemost 1997;78:1286-92.
47. Nilsson T, Sjoling-Ericksson A, Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J Enzyme Inhib 1998;13:11-29.
48. Klement P, Carlsson S, Rak J, et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in rabbit arterial thrombosis prevention and bleeding models. J Thromb Haemost 2003;1:587-94.
49. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999;94:187-97.
50. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulation therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-81.
51. Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of direct thrombin inhibitors in anesthetized rats and rabbits. Thromb Res 2001;101:159-70.
52. Elg M, Carlsson S, Gustafsson D. Effects of activated prothrombin complex concentrates or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001;101:145-57.
53. Gruber A, Carlsson S, Kotz H, Sarich TC, Marzec U, Hanson SR. Activated factor VII is hemostatic without promoting thrombus propagation [abstr]. Blood 2003;102:809a.
54. Elg M, Martinsson R, Carlsson S, Gustafsson D. Prolonged bleeding time induced by a direct thrombin inhibitor is reversed by recombinant factor Vila in anesthetized rats pretreated with lipopolysaccharide [abstr]. Pathophysiol Haemost Thromb 2002;32(suppl 2):131.
55. Wallentin L, Wilcox RG, Weaver WD. Oral ximelagatran for secondary prophylaxis after myocardial infraction: the ESTEEM randomized controlled trial. Lancet 2003;362:789-97.
56. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349(18):1713-21.
57. Francis CW, Ginsberg JS, Berkowitz SD, et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study [abstr]. Blood 2003;102(Pt 1):6a.
58. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003;41:1445-51.
59. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized controlled trial. Lancet 2003;362:1691-8.
60. The SPORTIF V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V) [abstr]. Circulation 2003;108:2723.
61. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
62. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 2003;10:2119-30.